Ensign Peak Advisors
SANA icon

Ensign Peak Advisors’s Sana Biotechnology SANA Stock Holding History

Ensign Peak Advisors’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-72,050
Closed -$300K – 1724
2024
Q3 		$300K Buy
72,050
+4,000
+6% +$21K ﹤0.01% 1675
2024
Q2 		$372K Buy
+68,050
New +$542K ﹤0.01% 1662
2023
Q1 		– Sell
-164,638
Closed -$650K – 1786
2022
Q4 		$650K Sell
164,638
-9,503
-5% -$46.5K ﹤0.01% 1509
2022
Q3 		$1.04M Sell
174,141
-130,318
-43% -$940K ﹤0.01% 1043
2022
Q2 		$1.96M Sell
304,459
-72,751
-19% -$463K ﹤0.01% 810
2022
Q1 		$3.12M Sell
377,210
-4,983
-1% -$40.3K 0.01% 721
2021
Q4 		$5.92M Sell
382,193
-234
-0.1% -$4.51K 0.01% 616
2021
Q3 		$8.61M Sell
382,427
-6,362
-2% -$134K 0.02% 471
2021
Q2 		$7.64M Buy
388,789
+18
+0% +$408 0.02% 507
2021
Q1 		$13M Buy
+388,771
New +$12.7M 0.03% 372

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's SANA Position: Q4 2024 in Review

Ensign Peak Advisors sold out of Sana Biotechnology (SANA) in Q4 2024, closing a stake of 72,050 shares — an estimated $300K sold.

Ensign Peak Advisors first reported a position in SANA in Q1 2021 and held it in 10 quarters. The position peaked at $13M in Q1 2021. 164 funds tracked by Wall St. Rank hold SANA as of Q4 2024.

  • Ensign Peak Advisors reported no remaining Sana Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 72,050 Sana Biotechnology shares in Q4 2024, an estimated $300K.
  • Ensign Peak Advisors first reported a position in Sana Biotechnology in Q1 2021 and held it in 10 quarters.
  • Ensign Peak Advisors's Sana Biotechnology position peaked at $13M in Q1 2021.
  • 164 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2024.

Based on Ensign Peak Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.